<DOC>
	<DOCNO>NCT02959190</DOCNO>
	<brief_summary>The main purpose study evaluate safety effectiveness study drug know Galcanezumab Japanese participant migraine .</brief_summary>
	<brief_title>A Study LY2951742 ( Galcanezumab ) Japanese Participants With Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>For Episodic Migraine participant : Participants complete treatment period Galcanezumab study CGAN . Have diagnosis chronic migraine define International Headache Society ( IHS ) International Classification Headache Disorders ( ICHD ) 3 beta guideline ( 1.3 ) ( ICHD3 2013 ) , history migraine headache least 1 year prior screening , migraine onset prior age 50 . For Chronic Migraine participant : Are currently enrol participate within last 30 day within 5 halflives ( whichever longer ) clinical trial involve investigational product . Current use prior exposure Galcanezumab antibodies CGRP receptor . Known hypersensitivity multiple drug , monoclonal antibody therapeutic protein , Galcanezumab excipients investigational product . History persistent daily headache , cluster headache migraine subtypes include hemiplegic ( sporadic familial ) migraine , ophthalmoplegic migraine , migraine brainstem aura ( basilartype migraine ) define IHS ICHD3 beta . Failure respond 3 adequately dosed migraine preventive treatment different class ( , maximum tolerate dose least 2 month ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>prevention</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>headache</keyword>
</DOC>